Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Neyt, Mattias" or (type exact bookEditor and editor="Neyt, Mattias")

Add to list
- Journal Article
- A4
Cost considerations for monoclonal antibody-targeted therapy in cancer: focus on Trastuzumab

Mattias Neyt

(2006) AMERICAN JOURNAL OF CANCER. 5(1). p.19-26
Add to list
- PhD Thesis
Economic evaluation of medical innovations

Mattias Neyt

(2006)
Add to list
- Journal Article
- A1
The long-term evolution of quality, of life for disease-free breast cancer survivors : a comparative study in Belgium

Mattias Neyt and Johan Albrecht (UGent)

(2006) JOURNAL OF PSYCHOSOCIAL ONCOLOGY. 24(3). p.89-123
Add to list
- Journal Article
- A1
An economic evaluation of Herceptin((R)) in adjuvant setting: The Breast Cancer International Research Group 006 trial

Mattias Neyt, Johan Albrecht (UGent) and Veronique Cocquyt (UGent)

(2006) ANNALS OF ONCOLOGY. 17(3). p.381-390
Add to list
- Miscellaneous
- open access
Bureaucratisation and the growth of health care expenditures in Europe

Johan Albrecht (UGent) , Mattias Neyt and Tom Verbeke (UGent)

(2005) Working Paper Faculteit Economie en Bedrijfskunde. 2005/335.
Add to list
- Journal Article
- A1
Cost-effectiveness of Herceptin (R): A standard cost model for breast-cancer treatment in a Belgian university hospital

Mattias Neyt, Johan Albrecht (UGent) , Bart Clarysse (UGent) and Veronique Cocquyt (UGent)

(2005) INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 21(1). p.132-137
Add to list
- Journal Article
- A1
Comparing the cost of delayed and immediate autologous breast reconstruction in Belgium

Mattias Neyt, Phillip Blondeel (UGent) , CM MORRISON and Johan Albrecht (UGent)

(2005) BRITISH JOURNAL OF PLASTIC SURGERY. 58(4). p.493-497

Academic Bibliography

Cost considerations for monoclonal antibody-targeted therapy in cancer: focus on Trastuzumab

Economic evaluation of medical innovations

The long-term evolution of quality, of life for disease-free breast cancer survivors : a comparative study in Belgium

An economic evaluation of Herceptin((R)) in adjuvant setting: The Breast Cancer International Research Group 006 trial

Bureaucratisation and the growth of health care expenditures in Europe

Cost-effectiveness of Herceptin (R): A standard cost model for breast-cancer treatment in a Belgian university hospital

Comparing the cost of delayed and immediate autologous breast reconstruction in Belgium

Contents

Support

Contact